1Demyttenaere K,Adelin A,Patrick M,et al.Six-month compliance with antidepressant medication in the treatment of major depressive disorder[J].Int Clin Psychopharmacol,2008,23(1):36-42.
2Bagby RM,Psych C,Quilty LC,et al.Personality and depression[J].Can J Psychiatry,2008,53(1):14-25.
3Dickel J,Veenstra-VanderWeele N,Bivens X,et al.Association studies of serotonin system candidate genes in early-onset obsessive-compulsive disorder[J].Biol Psychiatry,2007,61(3):322-329.
4Demyttenaere K,De Fruyt J,Stahl SM.The many faces of fatigue in major depressive disorder[J].Int J Neuropsychopharmacol,2005,8(1):93-105.
5Duman R,Malberg J,Nakagawa S,et al.Neuronal plasticity and survival in mood disorders[J].Biol Psychiatry,2000,48(8):732-739.
6Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibition in major depression[J].J Clin Psychiatry, 2012, 60(4) : 256-259.
7Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder [J]. J Clin Psychiatry, 2013, 56(9), 423-429.
8Fava M. The role of the serotonergic and noradrenergic neu- rotrans mitter systems in the treatment of psychological phys- ical symptoms of depression[J]. J Clin Psychiatry, 2013, 64 (13) : 26-29.
9Phillips MR, Zhang J, Shi Q, et al. Prevalence, treatment and associated disability of mental disorders in four provinces in China during 2001-05:an epidemiological survey [J]. The Lancet, 2012, 373(9680):2 041-2 053.
10Papakostas FL, Petersen TJ, Iosifescu DV, et al. Somatic symptoms as predictors of time to onset of response to fluoxe- tine in major depressive disorder [J]. J Clin Psychiatry, 2012, 65(12) :543-546.
